American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: Status report 2004

Journal of Clinical Oncology

Volumn 23, Issue 3, 2005, Pages 619-629

  Winer, Eric P ^a   Hudis, Clifford ^a   Burstein, Harold J ^a   Wolff, Antonio C ^a   Pritchard, Kathleen I ^a   Ingle, James N ^a   Chlebowski, Rowan T ^a   Gelber, Richard ^a   Edge, Stephan B ^a   Gralow, Julie ^a   Cobleigh, Melody A ^a   Mamounas, Eleftherios P ^a   Goldstein, Lori J ^a   Whelan, Timothy J ^a   Powles, Trevor J ^a   Bryant, John ^a   Perkins, Cheryl ^a   Perotti, Judy ^a   Braun, Susan ^a   Langer, Amy S ^a   Browman, George P ^a   Somerfield, Mark R ^a   more..

^a AMERICAN SOCIETY OF CLINICAL ONCOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; BIOLOGICAL MARKER; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN; EXEMESTANE; GOSERELIN; HORMONE RECEPTOR; LETROZOLE; PLACEBO; PROGESTERONE RECEPTOR; TAMOXIFEN; TRIPTORELIN; VOROZOLE; ESTROGEN RECEPTOR; TUMOR MARKER;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; AMENORRHEA; ARTHRALGIA; ARTICLE; BREAST CANCER; BREAST METASTASIS; CANCER RELAPSE; CANCER RISK; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; DEMENTIA; DRUG DOSE SEQUENCE; EARLY MENOPAUSE; ENDOMETRIUM CANCER; ESTRADIOL BLOOD LEVEL; FRACTURE; HORMONAL THERAPY; HOT FLUSH; HUMAN; LUNG EMBOLISM; MONOTHERAPY; MUSCULOSKELETAL DISEASE; MYALGIA; OSTEOLYSIS; OSTEOPOROSIS; OVARIECTOMY; PATIENT ASSESSMENT; POSTMENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; SEXUAL FUNCTION; SIDE EFFECT; STROKE; TREATMENT CONTRAINDICATION; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT PLANNING; VASCULAR DISEASE; AGED; BREAST TUMOR; FEMALE; MIDDLE AGED; PATHOLOGY; PROGNOSIS; REVIEW; RISK FACTOR; TUMOR RECURRENCE;

AGED; AROMATASE INHIBITORS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; POSTMENOPAUSE; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 20044382779     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.09.121     Document Type: Article

References (50)

1. Anonymous: Tamoxifen for early breast cancer: An overview of the randomised trials-Early Breast Cancer Trialists' Collaborative Group. Lancet 351:1451-1467, 1998
2. Baum M, on behalf of the ATAC Trialists' Group: The ATAC (Arimidex, Tamoxifen, Alone or in Combination) adjuvant breast cancer trial in post-menopausal women. Breast Cancer Res Treat 69, 2001 (abstr 8)
3. Winer EP, Hudis C, Burstein HJ, et al: American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer: Status report 2002. J Clin Oncol 20:3317-3327, 2002
4. Winer EP, Hudis C, Burstein HJ, et al: American Society of Clinical Oncology technology assessment working group update: Use of aromatase inhibitors in the adjuvant setting. J Clin Oncol 21:2597-2599, 2003
5. Coombes RC, Hall E, Gibson LJ, et al: A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 350:1081-1092, 2004
6. Goss PE, Ingle JN, Martino S, et al: Updated analysis of the NCIC CTG MA. 17 randomized placebo controlled trial of letrozole after five years of tamoxifen in postmenopausal women with early stage breast cancer. Proc Am Soc Clin Oncol 23:87, 2004 (abstr 847)
7. Whelan TJ, Goss PE, Ingle JN, et al: Assessment of quality of life in MA. 17, a randomized placebo-controlled trial of letrozole in postmenopausal women following five years of tamoxifen. Proc Am Soc Clin Oncol 23:6, 2004 (abstr 517)
8. Paridaens R, Therasse P, Dirix L, et al: First line hormonal treatment for metastatic breast cancer with exemestane or tamoxifen in postmenopausal patients: A randomized phase III trial of the EORTC Breast Group. Proc Am Soc Clin Oncol 23:6, 2004 (abstr 515)
9. Cameron DA, Winer EP, Campos S, et al: A comparative study of exemestane versus anastrozole in postmenopausal breast cancer subjects with visceral disease. Proc Am Soc Clin Oncol 23:34, 2004 (abstr 628)
10. Buzdar A, Douma J, Davidson N, et al: Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate. J Clin Oncol 19:3357-3366, 2001
11. Buzdar AU, Jones SE, Vogel CL, et al: A phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast carcinoma: Arimidex Study Group. Cancer 79:730-739, 1997
12. Bonneterre J, Buzdar A, Nabholtz JM, et al: Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Cancer 92:2247-2258, 2001
13. Nabholtz JM, Buzdar A, Pollak M, et al: Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: Results of a North American multicenter randomized trial-Arimidex Study Group. J Clin Oncol 18:3758-3767, 2000
14. Geisler J, Haynes B, Anker G, et al: Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study. J Clin Oncol 20:751-757, 2002
15. Rose C, Vtoraya O, Pluzanska A, et al: Letrozole (Femara) vs. anastrozole (Arimidex): second-line treatment in postmenopausal women with advanced breast cancer. Proc Am Soc Clin Oncol 21:34, 2002 (abstr 131)
16. Goss PE, Strasser K: Aromatase inhibitors in the treatment and prevention of breast cancer. J Clin Oncol 19:881-894, 2001
17. Baum M, Budzar AU, Cuzick J, et al: Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: First results of the ATAC randomised trial. Lancet 359:2131-2139, 2002
18. Boccardo F, Rubagotti A, Amoroso D, et al: Anastrozole appears to be superior to tamoxifen in women already receiving adjuvant tamoxifen treatment. Breast Cancer Res Treat 82:, 2003 (abstr 3)
19. Goss PE, Ingle JN, Martino S, et al: A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 349:1793-1802, 2003
20. Baum M, Buzdar A, Cuzick J, et al: Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: Results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer 98:1802-1810, 2003
21. Goss PE, Ingle JN, Martino S, et al: Updated analysis of the NCIC CTG MA. 17 randomized placebo (P) controlled trial of letrozole (L) after five years of tamoxifen in postmenopausal women with early stage breast cancer. Proc Am Soc Clin Oncol 23:87, 2004 (abstr 84)
22. Smith I, Dowsett M: Comparison of anastrozole vs. tamoxifen alone or in combination as neoadjuvant treatment of estrogen receptor-positive (ER+) operable breast cancer in postmenopausal women: The IMPACT trial. Breast Cancer Res Treat 82, 2003 (abstr 1)
23. Ellis MJ, Coop A, Singh B, et al: Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: Evidence from a phase III randomized trial. J Clin Oncol 19:3808-3816, 2001
24. Santen RJ, Song RX, Zhang Z, et al: Adaptive hypersensitivity to estrogen: Mechanism for sequential responses to hormonal therapy in breast cancer. Clin Cancer Res 10:337S-345S, 2004
25. Mouridsen H, Gershanovich M, Sun Y, et al: Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: Results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 19:2596-2606, 2001
26. Thurlimann B, Robertson JF, Nabholtz JM, et al: Efficacy of tamoxifen following anastrozole ("Arimidex") compared with anastrozole following tamoxifen as first-line treatment for advanced breast cancer in postmenopausal women. Eur J Cancer 39:2310-2317, 2003
27. Thurlimann B, Hess D, Koberle D, et al: Anastrozole ('Arimidex') versus tamoxifen as first-line therapy in postmenopausal women with advanced breast cancer: Results of the double-blind cross-over SAKK trial 21/95-a sub-study of the TARGET (Tamoxifen or 'Arimidex' Randomized Group Efficacy and Tolerability) trial. Breast Cancer Res Treat 85:247-254, 2004
28. Minton SE, Munster PN: Chemotherapy-induced amenorrhea and fertility in women undergoing adjuvant treatment for breast cancer. Cancer Control 9:466-472, 2002
29. Goodwin PJ, Ennis M, Pritchard KI, et al: Risk of menopause during the first year after breast cancer diagnosis. J Clin Oncol 17:2365-2370, 1999
30. Braverman AS, Sawhney A, Tendler A, et al: Premenopausal serum estradiol levels may persist after chemotherapy-induced amenorrhea in breast cancer. Proc Am Soc Clin Oncol 21:42, 2002 (abstr 164)
31. Dowsett M, Stein RC, Coombes RC: Aromatization inhibition alone or in combination with GnRH agonists for the treatment of premenopausal breast cancer patients. J Steroid Biochem Mol Biol 43:155-159, 1992
32. Mitwally MF, Casper RF: Use of an aromatase inhibitor for induction of ovulation in patients with an inadequate response to clomiphene citrate. Fertil Steril 75:305-309, 2001
33. Dowsett M, Doody D, Miall S, et al: Vorozole results in greater oestrogen suppression than formestane in postmenopausal women and when added to goserelin in premenopausal women with advanced breast cancer. Breast Cancer Res Treat 56:25-34, 1999
34. Cheung KL, Forward DP, Jackson L, et al: Combined use of goserelin (Zoladex) and anastrozole (Arimidex) as second-line endocrine therapy in premenopausal women with advanced breast cancer: A study of its clinical and endocrine effects. Eur J Cancer 37, 2001(suppl 1)
35. Howell A: Effect of anastrazole on bone minderaly density: 2-year results of "arimidex" (anastrazole), tamoxifen, alone or in combination (ATAC) trial. Breast Cancer Res Treat 82, 2003 (abstr 129)
36. Kanis JA, Oden A, Johnell O, et al: The components of excess mortality after hip fracture. Bone 32:468-473, 2003
37. Lonning PE, Geisler J, Krag LE, et al: Effect of exemestane on bone: A randomized placebo controlled study in postmenopausal women with early breast cancer at low risk. Proc Am Soc Clin Oncol 23:7, 2004 (abstr 518)
38. Gnant M, Hausmaninger H, Samonigg D, et al: Changes in bone mineral density caused by anastrazole or tamoxifen in combination with goserelin (+/- zoledronate) as adjuvant treatment for hormone receptor-positive premenopausal breast cancer: Results of a randomized multicenter trial. Breast Cancer Res Treat 76:531, 2002 (suppl)
39. Saarto T, Blomqvist C, Valimaki M, et al: Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: A randomized study in premenopausal breast cancer patients. J Clin Oncol 15:1341-1347, 1997
40. Saarto T, Vehmanen L, Elomaa I, et al: The effect of clodronate and antioestrogens on bone loss associated with oestrogen withdrawal in postmenopausal women with breast cancer. Br J Cancer 84:1047-1051, 2001
41. Delmas PD, Balena R, Confravreux E, et al: Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: A double-blind, placebo-controlled study. J Clin Oncol 15:955-962, 1997
42. Force USPST: Screening for osteoporosis in postmenopausal women: Recommendations and rationale. Ann Intern Med 137:526-528, 2002
43. Hillner BE, Ingle JN, Chlebowski RT, et al: American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 21:4042-4057, 2003
44. Powles TJ, Paterson E, McCloskey M, et al: Oral clodronate for adjuvant treatment of operable breast cancer: Results of a randomized, double-blind, placebo-controlled multicenter trial. Proceedings from the American Society of Clinical Oncology 23:9, 2004 (abstr 528)
45. Chlebowski RT, Col N, Winer EP, et al: American Society of Clinical Oncology technology assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene, and aromatase inhibition. J Clin Oncol 20:3328-3343, 2002
46. Fallowfield LJ, Cella DF, CRC Oncology Group: Assessing the quality of life of postmenopausal women randomized into the ATAC adjuvant breast cancer trial. Proc Am Soc Clin Oncol 21:40, 2002 (abstr 159)
47. Shumaker SA, Legault C, Rapp SR, et al: Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: The Women's Health Initiative Memory Study-A randomized controlled trial. JAMA 289:2651-2662, 2003
48. Clinical alert: NIH asks perticipants in Women's Health Initiative estrogen-alone study to stop study pills, begin follow-up phase. http://www.nlm.nih.gov/databases/alerts/estrogen_alone.html
49. Burstein HJ, Winer EP: Primary care for survivors of breast cancer. N Engl J Med 343:1086-1094, 2000
50. Chlebowski RT, Kim JA, Col NF: Estrogen deficiency symptom management in breast cancer survivors in the changing context of menopausal hormone therapy. Semin Oncol 30:776-788, 2003